Stock Ratings / Health Care / CCCC / financials

TECX (37) AUTL (25) AGMB (51) FENC (36) ⌘ Pro Terminal →

C4 Therapeutics Inc. (CCCC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.30 -2.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

C4 Therapeutics Inc. (CCCC) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $406.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCCC)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CCCC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $20.8M

FY24

Rev $35.6M

FY25

Rev $35.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$35.9M	52%	-80%	-$105.0M	-$99.3M	-45%
FY 2024	$35.6M	52%	-80%	-$105.3M	-$65.3M	-45%
FY 2023	$20.8M	52%	-80%	-$132.5M	-$106.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CCCC)

✓Walkthrough of CCCC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CCCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.61%⚡ TESTING RESISTANCE

2026-10-30O $3.23H $3.38L $3.21C $3.30VOL 2.35M

RES: $3.50SUP: $2.41SMA50: $3.32SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCCC Butterfly Map → + Track CCCC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CCCC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CCCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCCC)

Health Care Rank #977 of 1016 ⚔️ TECX vs CCCC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCCC vs. TECX, AUTL, AGMB, FENC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, C4 Therapeutics Inc. (CCCC) ranks #977 by composite RQD confidence (27/100, grade E) and #478 by equity capitalization ($406.0M). Within this direct 5-issuer industry benchmark cohort, CCCC leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CCCC at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CCCC ACTIVE C4 Therapeutics Inc.	E	27/100	—	—	-35.0%	-2.80%	$406.0M	Benchmark Subject
TECX Tectonic Therapeutic Inc.	D-	37/100	—	—	-35.0%	-0.29%	$400.8M	/tecx-vs-cccc →
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-cccc →
AGMB AgomAb Therapeutics NV	D	51/100	—	—	—	-0.13%	$391.5M	/agmb-vs-cccc →
FENC Fennec Pharmaceuticals Inc.	D-	36/100	—	—	-25.9%	+0.74%	$383.6M	/fenc-vs-cccc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001662579

In its most recent audited fiscal period (FY2025, filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported GAAP revenue of $35.9M (+1.0% vs. FY2024 revenue of $35.6M , and +73.2% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$98.7M, and free cash flow of -$99.3M (-52.0% YoY). On the balance sheet, CCCC closed FY2025 with $359.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.9M	-$105.0M	-$98.7M	-$99.3M	$359.1M	—
FY2024 (FY)	2024-12-31	$35.6M	-$105.3M	-$65.2M	-$65.3M	$349.6M	—
FY2023 (FY)	2023-12-31	$20.8M	-$132.5M	-$106.8M	-$106.8M	—	—

3. CCCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $3.30 (-2.80% 1D, market cap $406.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CCCC ranks #977 in composite RQD confidence.

How does CCCC compare to TECX and AUTL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TECX (Tectonic Therapeutic Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M) and AUTL (Autolus Therapeutics plc) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $420.5M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CCCC?

Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CCCC trading relative to its 50-day, 200-day, and 52-week technical levels?

CCCC last traded at $3.30 (-2.80% on volume of 2,715,045 shares), positioning the stock -0.60% below its 50-day simple moving average ($3.32) and +2.80% above its 200-day simple moving average ($3.21). Across its 52-week range of $1.69 to $5.17, CCCC sits at the 46.3% percentile with a 14-day RSI of 57.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.89 to $3.71).

CCCC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is C4 Therapeutics Inc. (CCCC)?

In FY 2025 (10-K), CCCC converted $35.9M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CCCC RQD Cockpit CCCC 12M Forecast CCCC Earnings & Move CCCC Dividends & DRIP CCCC Insiders & 13F CCCC Whale Options CCCC Profit Sankey CCCC News & Why